This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs ...

This report provides a comprehensive review of 27 candidate therapeutic antibodies that are being evaluated for the treatment of lung cancer; covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 potential targets.
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs ...

This report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the vaccines are directed at 24 antigens or antigen combinations.
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) ...

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
There are today 335 (298) companies plus partners developing 442 (384) lung cancer drugs in 508 (435) ...

Globally, Breast Cancer Is The Second Most Common Cancer after Lung Cancer....
....and the most common cancer for women. IT is the second most common cause of death from cancer in women after lung cancer.
The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.
Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in ...